Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
4DMedical Ltd ( (AU:4DX) ) just unveiled an update.
4DMedical Ltd, an ASX-listed medtech company specialising in lung imaging and respiratory diagnostic technologies, continues to build its capital base to support its commercial and development activities. The company operates under the ticker 4DX and targets clinicians and health systems seeking advanced tools for assessing lung function and respiratory disease.
The company has announced a proposed placement of up to 14,067,797 new fully paid ordinary shares. The new securities are expected to be issued on 2 April 2026, indicating a move to raise additional equity capital that may strengthen its balance sheet and fund ongoing growth initiatives, with implications for existing shareholder dilution and future expansion capacity.
The most recent analyst rating on (AU:4DX) stock is a Hold with a A$6.00 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Ltd is an Australian-listed medical technology company focused on lung imaging and respiratory diagnostics. Trading on the ASX under the code 4DX, it develops and commercialises software and imaging solutions designed to improve the assessment and management of lung function for healthcare providers and patients.
Average Trading Volume: 7,573,431
Technical Sentiment Signal: Buy
Current Market Cap: A$3.58B
Find detailed analytics on 4DX stock on TipRanks’ Stock Analysis page.